Revenues from Contracts and Significant Customers

6 Months Ended

Jun. 30, 2022

Revenues from Contracts and Significant Customers

Revenues from Contracts and Significant Customers

16. Revenues from Contracts and Significant Customers

Disaggregation of Total Revenue

Journey has the following actively marketed products, Qbrexza®, Accutane®, Targadox®, Ximino®, Exelderm®, Luxamend®, Amzeeq® and Zilxi®. All of Journey’s product revenues are recorded in the U.S. The Company’s collaboration revenue is from Cyprium’s agreement with Sentynl (see Note 3). The Company’s related party revenue is from Checkpoint’s collaborations with TGTX (see Note 14). Other revenue consists of a net $2.5 million milestone payment made to Journey triggered by Qbrexza® (Rapifort® Wipes 2.5%) receiving manufacturing and marketing approval in Japan in February 2022.

The net $2.5 million milestone payment reflects a milestone payment of $10 million to Journey from their exclusive licensing partner in Japan, Maruho Co., Ltd. (“Maruho”), offset by a $7.5 million payment to Dermira, pursuant to the terms of the Qbrexza APA between Journey and Dermira.  The table below summarizes the Company’s revenue for the three and six months ending June 30, 2022 and 2021:

	Three months ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Revenue
Qbrexza®	$	6,111	$	4,568	$	13,487		4,568
Accutane®		5,200		1,945		10,107		2,141
Amzeeq®		1,265		—		4,731		—
Targadox®		2,756		5,727		5,390	$	12,926
Ximino®		1,035		1,312		2,002		3,413
Zilxi®		555		—		1,297		—
Exelderm®		1,313		1,736		2,017		2,953
Other branded revenue		—		—		—		6
Collaboration revenue		577		2,400		1,154		3,200
Revenue – related party		18		155		70		223
Other revenue		56		—		2,556		—
Net revenue	$	18,886	$	17,843	$	42,811	$	29,430

The above table includes the authorized generic product within the line items for Targadox®, Ximino® and Exelderm®.

Significant Customers

For the three-month periods ending June 30, 2022 and 2021, none of the Company’s dermatology products customers accounted for more than 10% of its total gross product revenue.

For the six month periods ending June 30, 2022 and 2021, none of the Company’s dermatology products customers accounted for more than 10% of its total gross product revenue.

At June 30, 2022 and December 31, 2021, two of the Company’s dermatology products customers accounted for more than 10% of its total accounts receivable balance.